Imaging & Cognition | NYU Langone Health

Skip to Main Content
Charvet Lab Research Imaging & Cognition

Imaging & Cognition

Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its biological basis, and therefore identifying targeted options for management. First is the absence of a sensitive and precise measure of cognitive impairment. Second is the absence of an index of disease status linked to brain pathophysiology and cognitive performance. This project overcomes both obstacles to link cognitive impairment to MS disease biomarkers. The absence of a sensitive and precise measure of cognitive impairment, along with the absence of an index of disease status linked to brain pathophysiology and cognitive performance, limits the understanding of the biological basis for MS. This project overcomes both obstacles to link cognitive function to MS disease biomarkers, and provides preliminary evaluation of a disease modifying therapy (Tecfidera®️) for preserving cognitive function.

Learn more about this study.

(Please note that Internet Explorer users should consider disabling their ad blocker or using a different browser to properly access the form.)

 
Charvet lab staff review cognitive test data
Advanced neuroimaging techniques along with cognitive testing are used to detect subtle changes in functioning early in the disease process.

 

Magnetic resonance imaging scanner
Imaging allows us to study the activity of neurons in great detail to better understand how cognitive functioning may be affected by the disease.